Ravindra (Ravi) Majeti MD, PhD

Stanford University
Department of Medicine
Division of Hematology
Cancer Institute
Institute for Stem Cell Biology and Regenerative Medicine

Lokey Stem Cell Building
265 Campus Drive, G3167A
Stanford, CA 94305
(ph) 650-721-6376
rmajeti@stanford.edu
http://majetilab.stanford.edu

Positions, Education, and Training

Virginia and D.K. Ludwig Professor – Stanford University	10/2023-current
RZ Cao Endowed Professor – Stanford University	10/7/2020-10/2023
Professor of Medicine, Division of Hematology – Stanford University	9/1/2018-current
Associate Professor of Medicine, Division of Hematology – Stanford University	11/1/2015-8/31/2018
Assistant Professor of Medicine, Division of Hematology – Stanford University	5/01/2009-10/31/2015
Instructor in Medicine, Division of Hematology - Stanford University	2007-2009
Fellowship in Hematology - Stanford University, Stanford, CA	2004-2007
Residency in Internal Medicine - Brigham & Women's Hospital, Boston, MA	2002-2004
MD - University of California, San Francisco (UCSF), San Francisco, CA	June 2002
PhD in Biomedical Sciences - UCSF, San Francisco, CA	August 2000
AB in Biochemical Sciences - Harvard University, Cambridge, MA	June 1994

Leadership Positions

Director, Stanford Ludwig Center for Cancer Stem Cell Research and Medicine	2023-current
Director, Institute for Stem Cell Biology and Regenerative Medicine – Stanford Univ	2022-current
PI, T32 Program in Translational and Experimental Hematology (NHLBI)	2019-current
Chief, Division of Hematology – Stanford University	2017-2022
Co-Director Hematologic Malignancies Program, Stanford Cancer Institute	2014-2023
Assoc. Director, Stanford Ludwig Center for Cancer Stem Cell Research and Medicine	2014-2023
Stanford Leadership Academy	2019-2020
Stanford Medicine Leadership Academy	2014-2015
Co-Director Stanford Translational Investigator Pathway, Internal Medicine Residency	2013-2017
CD47 CIRM Disease Team Program – Co-Leader/Co-Principle Investigator	2010-2015

Honors

ISEH – Till and McCulloch Award	2024
Clifford Prize for Cancer Research	2023
Ernest Beutler Memorial Lecture, Acute Leukemia Forum	2022
Association of American Physicians, Member	2021
Leukemia and Lymphoma Society – 2020 CDP Achievement Award	2020
American Society for Clinical Investigation, Member	2017
Lorie Strauss Visiting Leukemia Professor, Memorial Sloan Kettering Cancer Center	2016
Leukemia and Lymphoma Society – Scholar Award	2015
New York Stem Cell Foundation – Robertson Stem Cell Investigator	2011
Burroughs Wellcome Fund Career Award for Medical Scientists	2008
Helen Hay Whitney Fellowship (declined)	2006
MSTP Fellowship – UCSF	1994
Summa Cum Laude - Harvard College	1994
Phi Beta Kappa - Harvard College	1994

Professional Societies, License, and Certification

American Board of Internal Medicine – Subspecialty Certification in Hematology	2007- current
American Board of Internal Medicine – Diplomate in Internal Medicine	2005
Medical Board of California – Physician and Surgeon License	2004-current
American Society of Hematology, Myeloid Neoplasia Scientific Committee	2013-2018
American Society of Hematology, Myeloid Neoplasia Scientific Committee, Chair	2018
American Society of Hematology, Committee on Scientific Affairs	2019-2022
American Society of Hematology, Blood Journal Editorial Board Member	2017-current
eLife, Reviewing Editor	2018-2020
American Association for Cancer Research, Hematologic Malignancies Task Force	2018-current
Cancer Discovery, Editorial Board	2020-current
NIH, Molecular and Cellular Hematology Study Section	2020
Cell Stem Cell, Advisory Board	2020-2023
NIH, Cancer Molecular Pathobiology Study Section	2021-2022
AACR Meeting on Clonal Hematopoiesis, Co-Chair	2021
AACR Meeting, AML and MDS, Co-Chair	2023
AACR Progress Report 2023, Steering Committee	2023

Publications (*indicates equal authorship)

Peer-Reviewed

1. Amaya L, Abe B, Liu J, Zhao F, Zhang WL, Chen R, Li R, Wang S, Kamber RA, Tsai MC, Bassik MC, **Majeti R**, Chang HY. *Pathways for macrophage uptake of cell-free circular RNAs*. Molecular Cell, epub (2024)
2. Sayitoglu EC, Luca BA, Boss AP, Thomas BC, Freeborn RA, Uyeda MJ, Chen PP, Nakauchi Y, Waichler C, Lacayo N, Bacchetta R, **Majeti R**, Gentles AJ, Cepika AM, Roncarolo MG. *AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML*. Leukemia, 38: 1246-1255 (2024)
3. Nuno K, Azizi A, Koehnke T, Lareau C, Ediriwickrema A, Corces MR, Satpathy AT, **Majeti R.** *Convergent epigenetic evolution drives relapse in acute myeloid leukemia*. eLife, epub (2024)
4. Suchy FP, Karigane D, Nakauchi Y, Higuchi M, Zhang J, Pekrun K, Hsu I, Fan AC, Nishimura T, Charlesworth CT, Bhadury J, Nishimura T, Wilkinson AC, Kay MA, **Majeti R***, Nakauchi H.* *Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors*. Nature Biotechnology, epub (2024)
5. Fowler JL, Zheng SL, Nguyen A, Chen A, Xiong X, Chai T, Chen JY, Karigane D, Banuelos AM, Niizuma K, Kayamori K, Nishimura T, Cromer MK, Gonzalez-Perez D, Mason C, Liu DD, Yilmaz L, Miquerol L, Porteus MH, Luca VC, **Majeti R**, Nakauchi H, Red-Horse K, Weissman IL, Ang LT, Loh KM. *Lineage-tracing hematopoietic stem cell origins in vivo to efficiently make human HLF+ HOXA+ hematopoietic progenitors from pluripotent stem cells*. Developmental Cell, 59: 1110-1131 (2024)
6. Schwede M, Jahn K, Kuipers J, Miles LA, Bowman RL, Robinson T, Furudate K, Uryu H, Tanaka T, Sasaki Y, Ediriwickrema A, Benard B, Gentles AJ, Levine R, Beerenwinkel N, Takahashi K, **Majeti R.** *Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity*. Leukemia, epub (2024)
7. Köhnke T, Nuno KA, Alder CC, Gars EJ, Phan P, Fan AC, **Majeti R.** *Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119*. Blood Cancer Discovery, 5: 202-223 (2024)
8. Pavel-Dinu M, Gardner CL, Nakauchi Y, Kawai T, Delmonte OM, Palterer B, Bosticardo M, Pala F, Viel S, Malech HL, Ghanim HY, Bode NM, Kurgan GL, Detweiler AM, Vakulskas CA, Neff NF, Sheikali A, Menezes ST, Chrobok J, Hernández González EM, **Majeti R**, Notarangelo LD, Porteus MH. *Genetically corrected RAG2-SCID human hematopoietic stem cells restore V(D)J-recombinase and rescue lymphoid deficiency*. Blood Advances, 8: 1820-1833 (2024)

9. Landberg N, Köhnke T, Feng Y, Nakauchi Y, Fan AC, Linde MH, Karigane D, Lim K, Sinha R, Malcovati L, Thomas D, **Majeti R.** *IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation.* Blood Cancer Discovery, 5: 114-131 (2023)
10. Nakauchi Y, Ediriwickrema A, Martinez-Krams D, Zhao F, Rangavajhula A, Karigane D, **Majeti R.** *Simplified intrafemoral injections using live mice allow for continuous bone marrow analysis.* J Vis Exp, 10: 201 (2023)
11. Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, Volkmer JP, Chen JY, Stanger AMP, Lehmann A, Appiah B, Märklin M, Rücker-Braun E, Salih HR, Roerden M, Schroeder SM, Häring MF, Schlosser A, Schetelig J, Schmitz M, Boerries M, Köhler N, Lengerke C, **Majeti R**, Weissman IL, Rammensee HG, Walz JS. *Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells.* Blood Cancer Discovery, 4: 468-489 (2023)
12. Fan AC, Nakauchi Y, Bai L, Azizi A, Nuno KA, Zhao F, Koehnke T, Karigane D, Cruz-Hernandez D, Reinisch A, Khatri P, and **Majeti R**. *RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition.* Journal of Clinical Investigation: 133: e167053 (2023)
13. Kotini AG, Carcamo S, Cruz-Rodriguez N, Olszewska M, Wang T, Demircioglu D, Chang CJ, Bernard E, Chao MP, **Majeti R**, Luo H, Kharas MG, Hasson D, Papapetrou EP. *Patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukemia.* Blood Cancer Discovery, 4: 318-335 (2023)
14. Sconocchia T, Foßelteder J, Köhnke T, **Majeti R**, Reinisch A. *Engineering oncogenic heterozygous gain-of-function mutations in human hematopoietic stem and progenitor cells.* J. Vis Exp, 193 (2023)
15. Smith BAH, Deutzmann A, Correa KM, Delaveris CS, Dhanasekaran R, Dove CG, Sullivan DK, Wisnovsky S, Stark JC, Pluvinage JV, Swaminathan S, Riley NM, Rajan A, **Majeti R**, Felsher DW, Bertozzi CR. *MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.* P.N.A.S., 120: e2215376120 (2023)
16. Linde MH, Fan AC, Koehnke T, Trotman-Grant AC, Gurev SF, Phan P, Zhao F, Haddock NL, Nuno KA, Gars EJ, Stafford M, Marshall PL, Dove CG, Linde IL, Landberg N, Miller LP, Majzner RG, Zhang TY, and **Majeti R**. *Reprogramming cancer into antigen-presenting cells as a novel immunotherapy*. Cancer Discovery, 13: 1164-1185 (2023)
17. Thomas D, Wu M, Nakauchi Y, Cheng M, Thompson-Peach CA, Lim K, Landberg N, Kohnke T, Robinson N, Kaur S, Kutyna M, Stafford M, Hiwase D, Reinisch A, Peltz G, and **Majeti R**. *Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability*. Cancer Discovery, 13: 496-515 (2023)
18. Mabe NW, Huang M, Dalton GN, Alexe G, Schaefer DA, Geraghty AC, Robichaud AL, Conway AS, Khalid D, Mader MM, Belk JA, Ross KN, Sheffer M, Linde MH, Ly N, Yao W, Rotiroti MC, Smith BAH, Wernig M, Bertozzi CR, Monje M, Mitsiades CS, **Majeti R**, Satpathy AT, Stegmaier K, Majzner RG. *Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.* Nature Cancer, 3: 976-993 (2022)
19. Hnatiuk AP, Bruyneel AAN, Tailor D, Pandrala M, Dheeraj A, Li W, Serrano R, Feyen DAM, Vu MM, Amatya P, Gupta S, Nakauchi Y, Morgado I, Wiebking V, Liao R, Porteus MH, **Majeti R**, Malhotra SV, Mercola M. *Reengineering ponatinib to minimize cardiovascular toxicity.* Cancer Research, 82: 2777-2791 (2022)
20. Bassal MA, Samaraweera SE, Lim K, Benard BA, Bailey S, Kaur S, Leo P, Toubia J, Thompson-Peach C, Nguyen T, Maung KZY, Casolari DA, Iarossi DG, Pagani IS, Powell J, Pitson S, Natera S, Roessner U, Lewis ID, Brown AL, Tenen DG, Robinson N, Ross DM, **Majeti R**, Gonda TJ, Thomas D, D'Andrea RJ. *Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.* Nature Communications, 13: 2614 (2022)
21. Nakauchi Y, Azizi A, Thomas D, Corces MR, Reinisch A, Sharma R, Cruz Hernandez D, Köhnke T, Karigane D, Fan A, Martinez-Krams D, Stafford M, Kaur S, Dutta R, Phan P, Ediriwickrema A, McCarthy E, Ning Y, Phillips T, Ellison CK, Guler GD, Bergamaschi A, Ku CJ, Levy S, **Majeti R.** *The cell type-specific 5hmC landscape and dynamics of healthy human hematopoiesis and TET2-mutant preleukemia.* Blood Cancer Discovery, 3: 346-367 (2022)
22. Lo YC, Keyes TJ, Jager A, Sarno J, Domizi P, **Majeti R**, Sakamoto KM, Lacayo N, Mullighan CG, Waters J, Sahaf B, Bendall SC, Davis KL.. *Cytofin enables intergrated analysis of public mass cytometry datasets using generalized anchors.* Nature Communications, 13: 934 (2022)
23. Theruvath J, Menard M, Smith BAH, Linde MH, Coles GL, Dalton GN, Wu W, Kiru L, Delaidelli A, Sotillo E, Silberstein JL, Geraghty AC, Banuelos A, Radosevich MT, Dhingra S, Heitzeneder S, Tousley A,

Lattin J, Xu P, Huang J, Nasholm N, He A, Kuo TC, Sangalang ERB, Pons J, Barkal A, Brewer RE, Marjon KD, Vilches-Moure JG, Marshall PL, Fernandes R, Monje M, Cochran JR, Sorensen PH, Daldrup-Link HE, Weissman IL, Sage J, **Majeti R**, Bertozzi CR, Weiss WA, Mackall CL, Majzner RG. *Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.* Nature Medicine, 28: 333-344 (2022)

24. Benard BA, Leak LB, Azizi A, Thomas D, Gentles AJ, and **Majeti R**. *Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.* Nature Communications, 12: 7244 (2021)
25. Richards RM, Zhao F, Freitas KA, Parker KR, XU P, Fan A, Sotillo E, Daugaard M, Oo HZ, Liu J, Hong W-J, Sorensen PH, Chang HY, Satpathy AT, Majzer RG, **Majeti R***, and Mackall CL*. *NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity.* Blood Cancer Discovery, 2: 648-665 (2021)
26. Romine KA, Nechiporuk T, Bottomly D, Jeng S, McSweeney SK, Kaempf A, Corces MR, **Majeti R**, and Tyner JW. *Monocytic differentiation and AHR signaling as primary nodes of BET inhibitor response in acute myeloid leukemia.* Blood Cancer Discovery, 2: 518-531 (2021)
27. Cromer ML, Camarena J, Martin RM, Lesch BL, Vakulskas CA, Bode NM, Kurgan G, Collingwood MA, Rettig GR, Behlke MA, Lemgart VT, Zhang Y, Goyal A, Zhao F, Ponce E, Srifa W, Bak RO, Uchida N, **Majeti R**, Sheehan VA, Tisdale JF, Dever DP, and Poteus M. *Gene replacement of a-globin with b-globin restores hemoglobin balance in b-thalassemia-derived hematopoietic stem and progenitor cells.* Nature Medicine, 27: 677-687 (2021)
28. Minhas, PS, Latif-Hernandez A, McReynolds MR, Durairaj AS, Wang Q, Rubin A, Joshi AU, He JQ, Gauba E, Liu J, Wang C, Linde M, Sugiura Y, Moon PK, **Majeti R**, Suematsu M, Mochly-Rosen D, Weissman IL, Longo FM, Rabinowitz JD, and Adreasson KI. *Restoring metabolism of myeloid cells reverses cognitive decline in ageing*. Nature, 590: 122-128 (2021)
29. Sharma R*, Dever DP*, Lee CM*, Azizi A*, Pan Y, Camarena J, Koehnke T, Bao G*, Porteus MH*, and **Majeti R***. *The TRACE-Seq method tracks recombination alleles and identified clonal reconstitution dynamics of gene targeted human hematopoietic stem cells.* Nature Communications, 12: 472 (2021)
30. Mantri S, Reinisch A, Dejene BT, Lyell DJ, DiGusto DL, Agarwal-Hashmi R, **Majeti R**, Weinberg KI, and Porteus MH. *CD34 expression does not correlate with immunophenotypic stem cell or progenitor content in human cord blood products.* Blood Advances, 4: 5357-5361 (2020)
31. Zhang H, Nkauchi Y, Koehnke T, Stafford M, Bottomly D, Thomas R, Wilmot B, McWeeney SK, **Majeti R***, and Tyner JW. *Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.* Nature Cancer, 1: 826-839 (2020)
32. Nishimura T, Xu H, Iwasaki M, Karigane D, Saavedra B, Takahashi Y, Suchi FP, Monobe S, Martin RM, Ohtaka M, Nakanishi M, Burrows SR, Cleary ML, **Majeti R**, Shibuya A, and Nakauchi H. *Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cells.* Gene Therapy, epub (2020)
33. Azizi A, Ediriwickrema A, Dutta R, Patel SA, Shomali W, Medeiros B, Iberri D, Gotlib J, Mannis G, Greenberg P, **Majeti R**, and Zhang T. *Venetoclax and hypomethylating agent therapy in high risk myelodysplastic sydromes: a retrospective evaluation of a real-world experience.* Leukemia and Lymphoma, 16: 1-8 (2020)
34. Liu J, Xavy S, Mihardja S, Chen S, Sompali K, Feng D, Choi TS, Agoram B, **Majeti R**, Weissman IL, and Volkmer JP. *Targeting macrophage checkpoint inhibitor SIRPa for anticancer therapy.* JCI Insight, 19: 134728 (2020)
35. Zhang TY, Dutta R, Benard B, Zhao F, Yin R, and **Majeti R**. *IL-6 reverses bone marrow failure induced by human acute myeloid leukemia*. Science Translational Medicine, 12: eaax5104 (2020)
36. Ediriwickrema A, Aleshin A, Reiter JG, Corces MR, Kohnke T, Stafford M, Liedtke M, Medeiros BC, and **Majeti R**. *Single-cell mutational profiling enhances the clinical evaluation of AML MRD*. Blood Advances, 4: 943-952 (2020)
37. Koldobskiy MA, Abante J, Jenkinson G, Pujadas E, Tetens A, Zhao F, Tryggvadottir R, Idrizi A, Reinisch A, **Majeti R**, Goutsias J, and Feinberg AP. *A dysregulated DNA methylation landscape linked to gene expression in MLL-rearranged AML*. Epigenetics, 29: 1-18 (2020)
38. Dutta R, Zhang TY, Koehnke T, Thomas D, Linde M, Gars E, Stafford M, Kaur S, Nakauchi Y, Yin R, Azizi A, Narla A, and **Majeti R**. *Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2*. J Clinical Investigation, 130: 1843-1849 (2020)

39. Nishimura T, Hsu I, Martinez-Krams DC, Nakauchi Y, **Majeti R**, Yamazaki S, Nakauchi H, Wilkinson AC. *Use of polyvinyl alcohol for chimeric antigen receptor T-cell expansion*. Exp Hematology, 80: 16-20 (2019)
40. Granja JM, Klemm S, McGinnis LM, Kathiria AS, Mezger A, Corces MR, Parks B, Gars E, Liedtke M, Zheng GXY, Chang HY, **Majeti R**, and Greenleaf W. *Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia*. Nature Biotechnology 37: 1458-1465 (2019)
41. Guan Y, Chen X, Wu M, Zhu W, Arslan A, Takeda S, Nguyen MH, **Majeti R**, Thomas D, Zheng M, and Peltz G. *The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy*. J Hepatology, S0168-8278 (2019)
42. Li Y, Thomas D, Deutzmann A, **Majeti R**, Felsher DW, and Dill DL. *Mebendazole for differentiation therapy of acute myeloid leukemia identified by a lineage maturation index.* Sci Reports, 9: 16775 (2019)
43. Xu J, Nuno K, Litzenburger UM, Qi Y, Corces MR, **Majeti R**, Chang HY. *Single cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA*. eLife, 8: e45105 (2019)
44. Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, **Majeti R**, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK. *First-in-Human, First-in-Class Phase I Trial of Anti-CD47 Antibody Hu5F9-G4 in Patients with Advanced Cancers*. Journal of Clinical Oncology, 946-953 (2019)
45. Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, St Croix B, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, **Majeti R**, Monje M, Sorensen PH, Maris JM, Mackall CL. *CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent pre-clinical activity against pediatric solid tumors and brain tumors.* Clinical Cancer Research, 2560-2574 (2019)
46. Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, **Majeti R**, Babon JJ, Lopez AF. *Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis*. Science Advances, 4: eaat3834 (2018)
47. Minhas PS, Liu L, Moon PK, Joshi AU, Dove C, Mhatre S, Contrepois K, Wang Q, Lee BA, Coronado M, Bernstein D, Snyder MP, Migaud M, **Majeti R**, Mochly-Rosen D, Rabinowitz JD, Andreasson KI. *Macrophage de novo NAD+ synthesis specifies immune function in aging and inflammation.* Nature Immunology, 20: 50-63 (2018)
48. Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, **Majeti R**, Weissman IL, Takimoto CH, Chao MP, Smith SM. *CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma*. N Engl J Med, 379: 1711-1721 (2018)
49. Chan CKF, Gulati GS, Sinha R, Tompkins JV, Lopez M, Carter AC, Ransom RC, Reinisch A, Wearda T, Murphy M, Brewer RE, Koepke LS, Marecic O, Manjunath A, Seo EY, Leavitt T, Lu WJ, Nguyen A, Conley SD, Salhotra A, Ambrosi TH, Borrelli MR, Siebel T, Chan K, Schallmoser K, Seita J, Sahoo D, Goodnough H, Bishop J, Gardner M, **Majeti R**, Wan DC, Goodman S, Weissman IL, Chang HY, Longaker MT. *Identification of the Human Skeletal Stem Cell*. Cell, 175: 43-56 (2018)
50. Buenrostro JD, Corces MR, Wu B, Schep AN, Lareau CA, **Majeti R**, Chang HY, and Greenleaf WJ. *Integrated single-cell analysis maps the continuous regulatory landscape of human hematopoietic differentiation*. Cell, 173: 1535-1548 (2018)
51. Karamitros D*, Stoilova B*, Aboukhalil Z, Hamey F, Reinisch A, Samitsch M, Quek L, Otto G, Repapi E, Doondeea J, Usukhbayar B, Calvo J, Taylor S, Goardon N, Six E, Pflumio F, Porcher C, **Majeti R**, Gottgens B, and Vyas P. *Functional and transcriptional heterogeneity of human hemopoietic lympho-myeloid progenitors at the single cell level*. Nature Immunology, 19: 85-97 (2017)
52. Bak RO*, Dever DP*, Reinisch A*, Cruz Hernandez D, **Majeti R***, and Porteus MH*. *Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6*. eLife, 6: e27873 (2017)
53. Reinisch A, Hernandez DC, Schallmoser K, and **Majeti R**. *Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice*. Nature Protocols, 12: 2169-2188 (2017)
54. McKeown MR*, Corces MR*, Eaton ML*, Fiore C*, Lee E, Lopez JT, Chen MW, Cmith D, Chan SM, Koenig JL, Austgen K, Guenther MG, Orlando DA, Loven J, Fritz CC, and **Majeti R**. *Superenhancer*

analysis defines novel epigenomic subtypes of non-APL AML, including an RARa dependency targetable by SY-1425, a potent and selective RARa agonist. Cancer Discovery, 7: 1136-1153 (2017)

55. Sinha S*, Thomas D*, Chan S, Gao Y, Brunen D, Torabi D, Reinisch A, Hernandez D, Chan A, Rankin EB, Bernards R, **Majeti R***, and Dill DL*. *Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data*. Nature Communications, 8: 15580 (2017)
56. Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G, Taylor MD, Monje M, Cho YJ, **Majeti R**, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, and Cheshier SH. *Disrupting the CD47-SIRPa anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors*. Science Translational Medicine, 9: 381 (2017)
57. Chao MP, Gentles AJ, Chatterjee S, Lan F, Reinisch A, Corces MR, Xavy S, Shen J, Haag D, Chanda S, Sinha R, Morganti RM, Nishimura T, Ameen M, Wu H, Wernig M, Wu JC, and **Majeti R**. *Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease.* Cell Stem Cell, 20:329-344 (2016)
58. Dever DP*, Bak RO*, Reinisch A, Camarena J, Washington G, Nicolas CE, Pavel-Dinu M, Saxena N, Wilkens AB, Mantri S, Uchida N, Hendel A, Narla A, **Majeti R**, Weinberg KI, and Porteus M. *CRISPR/Cas9 beta-globin gene targeting in human hematopoietic stem cells*. Nature, 539: 384-389 (2016)
59. Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, Chan SM, Lodi A, Sweeney SR, Ma H, Davis RE, Baran N, Haferlach T, Su X, Flores ER, Gonzalez D, Konoplev S, Samudio I, DiNardo C, **Majeti R**, Schimmer AD, Li W, Wang T, Tiziani S, and Konopleva M. *Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.* Oncotarget, 7: 79722-79735 (2016)
60. Huang M, Garcia JS, Thomas D, Zhu L, Nguyen LX, Chan SM, **Majeti R**, Medeiros BC, and Mitchell BS. *Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells*. Oncotarget, 7: 74917-74930 (2016)
61. Corces MR, Buenrostro J, Wu B, Greenside PG, Chan SM, Koenig JL, Snyder MP, Pritchard JK, Kundaje A, Greenleaf WJ, **Majeti R***, and Chang H*. *Lineage-specific and single cell chromatin accessibility charts human hematopoiesis and leukemia evolution*. Nature Genetics, 48: 1193-1203 (2016)
62. Jonas BA, Johnson C, Gratzinger D, and **Majeti R**. *Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity*. PLoS One, 11: e0159189 (2016)
63. Weiskopf K, Jahchan ND, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, **Majeti R**, Garcia KC, Weissman IL, and Sage J. *CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer*. Journal of Clinical Investigation, 126: 2610-2620 (2016)
64. Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D, Hong WJ, Schallmoser K, Strunk D, and **Majeti R**. *A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells.* Nature Medicine, 22: 812-821 (2016)
65. Zhu L, Li Q, Wong SH, Huang M, Klein BJ, Shen J, Ikenouye L, Onishi M, Schneidawind D, Buechele C, Hansen L, Duque-Afonso J, Zhu F, Mas Martin G, Gozani O, **Majeti R**, Kutateladze TG, and Cleary ML. *ASH1L links histone H3 lysine 36 di-methylation to MLL leukemia.* Cancer Discovery, 6: 770-783 (2016)
66. Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, Wang L, Weiskopf K, and **Majeti R**. *SIRP-a antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells.* Clinical Cancer Research, 22: 5109-5119 (2016)
67. Zhang M, Hutter G, Kahn SA, Azad TD, Gholamin S, Xu CY, Liu J, Achrol AS, Richard C, Sommerkamp P, Schoen MK, McCracken MN, **Majeti R**, Weissman I, Mitra SS, and Cheshier SH. *Anti-CD47 treatment stimulates phagocytosis of gliobastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo*. PLoS One, 11: e0153550 (2016)
68. Mazumdar C, Shen Y, Xavy S, Zhao F, Reinisch A, Li R, Corces-Zimmerman MR, Flynn RA, Buenrostro JD, Chan SM, Thomas D, Koenig JL, Hong WJ, Chang HY, and **Majeti R**. *Leukemia-associated cohesin*

mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. Cell Stem Cell, 17: 675-688 (2015)

69. Jung N*, Dai B*, Gentles AJ, **Majeti R***, and Feinberg A*. *An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis*. Nat Communications, 7: 8489 (2015)
70. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL*, and **Majeti R***. *Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential*. PLoS One, 10: e0137345 (2015)
71. Piccione EC, Juarez S, Liu J, Tseng S, Ryan C, Narayanan C, Wang L, Weiskopf K, and **Majeti R**. *A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells*. MAbs, 7: 946-956 (2015)
72. McClellan JS*, Dove CG*, Gentles AJ, Ryan CE, and **Majeti R**. *Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages*. P.N.A.S., 112: 4074-4079 (2015)
73. Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo, I Weissman IL, Minary P, **Majeti R**, Constantinescu SN, Piehler J, and Garcia KC. *Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands*. Cell, 160: 1196-1208 (2015)
74. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA, and **Majeti R**. *Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.* Nature Medicine, 21: 178-184 (2015)
75. Sinha S, Thomas D, Yu L, Gentles AJ, Jung N, Corces-Zimmerman MR, Chan SM, Reinisch A, Feinberg AP, Dill DL*, **Majeti R***. *Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition*. Blood, 125: 316-326 (2015)
76. Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, Hartwig UF, Beham-Schmid C, Trajanoski S, Lin Q, Wagner W, Dullin C, Alves F, Andreeff M, Weissman IL, Longaker MT, Schallmoser K, **Majeti R**, Strunk D. *Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation.* Blood, 125: 249-260 (2015)
77. Green MR, Vicente-Duenas C, Romero-Camarero I, Long Liu C, Dai B, Gonzalez-Herrero I, Garcia-Ramirez I, Alonso-Escudero E, Iqbal J, Chan WC, Campos-Sanchez E, Orfao A, Pintado B, Flores T, Blanco O, Jimenez R, Martinez-Climent JA, Criado FJ, Cenador MB, Zhao S, Natkunam Y, Lossos IS, **Majeti R**, Melnick A, Cobaleda C, Alizadeh AA, and Sanchez-Garcia I. *Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.* Nat Commun, 5: 3904 (2014).
78. Nguyen LX, Chan SM, Ngo TD, Raval A, Kim KK, **Majeti R**, and Mitchell BS. *Interaction of TIF-90 and filamin A in the regulation of rRNA synthesis in leukemic cells.* Blood, 124: 579-589 (2014)
79. Lee JY, Hong W, **Majeti R**, and Stearns T. *Centrosome-kinase fusions promote oncogenic signaling and disrupt centrosome function in myeloproliferative neoplasms.* PLoS One, 9: e92641 (2014)
80. Corces-Zimmerman MR, Hong W, Weissman IL, Medeiros BC, and **Majeti R**. *Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission*. P.N.A.S., 111: 2548-2553 (2014)
81. Huang M, Thomas D, Li MX, Feng W, Chan SM, **Majeti R**, and Mitchell BS. *Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib*. Leukemia, 27: 1970-1980 (2013)
82. Craddock C, Quek L, Goardon, N, Freeman S, Siddique S, Raghavan M, Aztberger A, Schuh A, Grimwade D, Ivery A, Virgo P, Hills R, McSkeane T, Arrazi J, Knapper S, Brookes C, Davies B, Price A, Wall K, Griffiths M, Cavenagh J, **Majeti R**, Weissman I, Burnett A, and Vyas P. *Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.* Leukemia, 27: 1028-1036 (2012)
83. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL*, Quake SR*, and **Majeti R***. *Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.* Science Translational Medicine, 4: 149ra118 (2012)
84. Ochsenreither S, **Majeti R**, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, and Greenberg P. *Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics*

of a cancer-testis antigen. Blood, 119: 5492-5501 (2012)

85. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, **Majeti R**, West RB, Fletcher JA, Beck AH, Weissman IL, and van de Rijn M. *Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.* P.N.A.S., 109: 6656-6661 (2012)
86. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PO, Steinberg GK, Li G, So SK, **Majeti R**, Harsh GR van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, and Weissman IL. *The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.* P.N.A.S., 109: 6662-6667 (2012)
87. McClellan JS, Kohrt HE, Coutre SS, Gotlib JR, **Majeti R**, Alizadeh AA, and Medeiros BC. *Treatment advances have not improved the early death rate in acute promyelocytic leukemia.* Haematologica, 97: 133-136 (2012)
88. Chao MP, Tang C, Pachynski RK, Chin R, **Majeti R***, and Weissman IL*. *Extra-nodal dissemination of non-Hodgkin's lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.* Blood, 118: 4890-4901 (2011)
89. Gibbs KD, Gilbert PM, Sachs K, Zhao F, Blau HM, Weissman IL, Nolan GP*, and **Majeti R***. *Single cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments*. Blood, 117: 4226-4233 (2011)
90. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, and **Majeti R**. *Prospective separation of normal and leukemia stem cells based on differential expression of TIM3, a human AML stem cell marker.* P.N.A.S., 108: 5009-5014 (2011)
91. Gentles AJ, Plevritis SK, **Majeti R***, and Alizadeh AA*. *Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.* JAMA, 304: 2706-15 (2010)
92. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, **Majeti R***, and Weissman IL*. *Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47.* Sci Transl Med, 2: 63ra94 (2010)
93. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL*, and **Majeti R***. *Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.* Cancer Res, 1:1374-84 (2011)
94. Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, **Majeti R**, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, and Medeiros BC. *Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.* Am J Hematol, 85: 877-81 (2010)
95. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL*, and **Majeti R***. *Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin Lymphoma.* Cell, 142: 699-713 (2010)
96. Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, **Majeti R**, Kogel KE, Azar CA, Patel S, and Alizadeh AA. *Immunophenotypic features of acute myeloid leukemia with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2)*. Leukemia Research, 34: 594-597 (2010)
97. **Majeti R***, Chao MP*, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, and Weissman IL. *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.* Cell, 138: 286-299 (2009)
98. Jaiswal S, Jamieson CHM, Pang WW, Park, CY, Chao MP, **Majeti R**, Traver D, van Rooijen N, and Weissman IL. *CD47 is up-regulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis*. Cell, 138: 271-285 (2009)
99. **Majeti R***, Becker MW*, Tian Q*, Lee M, Yan X, Liu R, Chiang J, Clarke MF, Hood, L, and Weissman IL. *Dysregulated gene expression networks in human acute myelogenous leukemia stem cells.* P.N.A.S., 106: 3396-3401 (2009)
100. Ooi AGL, Karsunky H, **Majeti R**, Butz S, Vestweber D, Ishida T, Quertermous T, Weissman IL, and Forsberg EC. *The adhesion molecule ESAM1 is a novel hematopoietic stem cell marker.* Stem Cells, 27: 653-661 (2009)

101. Park CY*, **Majeti R***, and Weissman IL. *In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood*. Nature Protocols, 3: 1932-1940 (2008)
102. **Majeti R***, Park CY*, and Weissman IL. *Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood*. Cell Stem Cell, 1:635-645 (2007)
103. Hermiston ML, Tan AL, Gupta VA, **Majeti R**, and Weiss A. *The juxtamembrane wedge negatively regulates CD45 function in B cells.* Immunity, 23: 635-647 (2005)
104. Baker JE, **Majeti R**, Tangye SG, and Weiss A. *Protein tyrosine phosphatase CD148-mediated inhibition of T cell receptor signal transduction occurs through the reduction of LAT and PLC-g phosphorylation*. Mol. Cell. Bio., 21: 2393-2403 (2001)
105. **Majeti R**, Xu Z, Parslow TG, Olson JL, Daikh DI, Killeen N, and Weiss A. *An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity*. Cell, 103: 1059-1070 (2000)
106. Lagunoff M, **Majeti R**, Weiss A, and Ganem D. *Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus*. P.N.A.S., 96: 5704-5709 (1999)
107. **Majeti R**, Bilwes AM, Noel JP, Hunter T, and Weiss A. *Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge.* Science, 279: 88-91 (1998)

Peer Reviewed Reviews

1. Daver NG, Maiti A, Kadia TM, Vyas P, **Majeti R**, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, and Kantarjan HM. *TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions*. Cancer Discovery, 12: 2516-2529 (2022)
2. Ediriwickrema A, Gentles AJ, and **Majeti R**. *Single cell genomics in AML: extending frontiers of AML research*. Blood, epub (2022)
3. **Majeti R**, Jamieson C, Pang WW, Jaiswal S, Leeper NJ, Wernig G, Weissman IL. *Clonal expansion of stem/progenitor cells in cancer, fibrotic diseases, and atherosclerosis, and CD47 protection of pathogenic cells.* Annual Review of Medicine, 73: 307-320 (2022)
4. Koehnke T and **Majeti R**. *Clonal hematopoiesis: from mechanisms to clinical intervention*. Cancer Discovery, 11: 2987-1997 (2021)
5. Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, Volkmer JP, Weissman IL, and **Majeti R**. *Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies.* Frontiers in Oncology, 9: 1380 (2020)
6. Benard B, Gentles AJ, Köhnke T, **Majeti R***, Thomas D*. *Data mining for mutation-specific targets in acute myeloid leukemia.* Leukemia, 33: 826-843 (2019)
7. Takimoto CH, Chao MP, Gibbs C, McCamish MA, Liu J, Chen JY, **Majeti R**, Weissman IL. *The macrophage "do not eat me" signal, CD47, is a clinically validated cancer immunotherapy target*. Annals of Oncology, 30: 486-489 (2019)
8. Chao MP and **Majeti R**. *Induced pluripotent stem cell modeling of malignant hematopoiesis.* Experimental Hematology, 71: 68-76 (2019)
9. Saygin C, Matei D, **Majeti R**, Reizes O, Lathia JD. *Targeting cancer stemness in the clinic: from hype to hope.* Cell Stem Cell, 24: 25-40 (2019)
10. Valent P, Akin C, Arock M, Bock C, George TI, Galli SJ, Gotlib J, Haferlach T, Hoermann G, Hermine O, Jäger U, Kenner L, Kreipe H, **Majeti R**, Metcalfe DD, Orfao A, Reiter A, Sperr WR, Staber PB, Sotlar K, Schiffer C, Superti-Furga G, Horny HP. *Proposed terminology and classification of pre-malignant neoplastic conditions: a consensus proposal*. EBioMedicine, 26:17-24 (2017)
11. Corces MR, Chang, HY, and **Majeti R**. *Pre-leukemic hematopoietic stem cells in human acute myeloid leukemia.* Frontiers in Oncology, 7: 263 (2017)
12. Thomas D and **Majeti R**. *Biology and relevance of human acute myeloid leukemia stem cells.* Blood, 129:1577-1585 (2017)
13. Mazumdar C and **Majeti R**. *The role of mutations in the cohesin complex in acute myeloid leukemia*. Int J Hematol, 105:31-36 (2017)
14. Sykes SM, Kokkaliaris KD, Milsom MD, Levine RL, and **Majeti R**. *Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia*. Exp Hematology, 43: 989-992 (2015)
15. Reinisch A, Chan SM, Thomas D, and **Majeti R**. *Biology and clinical relevance of acute myeloid leukemia stem cells*. Semin Hematol, 52: 150-164 (2015)

16. **Majeti R.** *Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia*. Best Pract Res Clin Haematol, 27: 229-234 (2014)
17. Corces-Zimmerman MR and **Majeti R**. *Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis.* Leukemia, 28: 2276-82. (2014)
18. Chan SM and **Majeti R**. *Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.* International Journal of Hematology, 98: 648-657 (2013)
19. Jan M and **Majeti R**. *Clonal evolution of acute leukemia genomes.* Oncogene, 10: 135-140 (2012)
20. Chao MP, Weissman IL*, and **Majeti R***. *The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications.* Current Opinion in Immunology, 24: 225-32 (2012)
21. Chao MP, **Majeti R***, and Weissman IL*. *Programmed cell removal: a new obstacle in the road to developing cancer.* Nature Reviews Cancer, 12: 58-67 (2011)
22. **Majeti R**. *Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.* Oncogene, 30:1009-19 (2011)
23. Jaiswal S, Chao MP, **Majeti R**, and Weissman IL. *Macrophages as mediators of tumor immunosurveillance*. Trends Immunol, 31**:** 212-219 (2010)
24. Hermiston ML, Xu Z, **Majeti R**, and Weiss A. *Reciprocal regulation of lymphocyte activation by tyrosine kinases and phosphatases*. J. Clin. Invest., 109: 9-14 (2002)
25. **Majeti R** and Weiss A. *Regulatory mechanisms for receptor protein tyrosine phosphatases.* Chemical Reviews, 101: 2441-2448 (2001)

Case Reports

1. Chao MP, Hong J, Kunder C, Lester L, Schrier SL, and **Majeti R**. *Refractory warm IgM-mediated autoimmune hemolytic anemia associated with Churg-Strauss Syndrome responsive to eculizumab and rituximab.* Am J Hematol, 90: 78-81 (2015)

Non-Peer Reviewed Commentaries

1. Zhang TY and **Majeti R**. *Targeting LSCs: Peeling back the curtain on the metabolic complexities of AML*. Cell Stem Cell, 27: 693-695 (2020)
2. Thomas R and **Majeti R**. *No matter how you splice it, RBM39 inhibition targets spliceosome mutant AML.* Cancer Cell, 35: 337-339 (2019)
3. Thomas D and **Majeti R**. *Optimizing next-generation AML therapy: activity of mutant IDH2 inhibitor AG-221 in preclinical models*. Cancer Discovery, 7: 459-461 (2017)
4. Reinisch A and **Majeti R**. *Sticking it to the niche: CD98 mediates critical adhesive signals in AML.* Cancer Cell, 14: 662-664 (2016)
5. Thomas D and **Majeti R**. *Burning Fat Fuels Leukemic Stem Cell Heterogeneity*. Cell Stem Cell, 7: 1-2 (2016)
6. McClellan JS and **Majeti R**. *The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould*. EMBO Mol Med, 5: 7-9 (2013)
7. Alizadeh AA and **Majeti R**. *Surprise! HSC are aberrant in chronic lymphocytic leukemia.* Cancer Cell, 20: 135-6 (2011)
8. **Majeti R** and Weissman IL. *Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye.* Cancer Cell, 19: 9-10 (2011)
9. Diehn, M and **Majeti R**. *Metastatic cancer stem cells: an opportunity for improving cancer treatment?* Cell Stem Cell*,* 6: 502-503 (2010)

Oral Presentations

1. 14th Myeloid Workshop, Cincinnati 5/22/2024
   Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
2. NCI, MDS Workshop 5/13/2024
   Title: *Pre-leukemic HSCs: Therapeutic Targeting and Clonal Expansion*
3. Cole Foundation, Annual Meeting 2024 5/3/2024
   Title: *Stem Cells and Reprogramming in Human Acute Leukemia*

4. AACR, Annual Meeting 2024 4/8/2024
   Title: *Pre-leukemic mutations and leukemia stem cells in human AML*
5. Intercepting Blood Cancers, Conference 3/14/2024
   Title: *CHIP mutations in pre-leukemia vs. frank AML with focus on DNMT3A*
6. FASEB, Hematologic Malignancies 2/28/2024
   Title: *Stem Cells in Human AML*
7. American Society of Hematology, 65th Annual Meeting, Scientific Workshop 12/08/2023
   Title: *Synthetic Lethal Metabolic Dependencies in IDH1-Mutant AML*
8. 10th Barossa Meeting, Cell Signaling to Cancer Medicine 11/14/2023
   Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
9. RUNX1 Research Program, 7th Annual Scientific Conference 11/2/2023
   Title: *Loss of BCOR Partially Rescues RUNX1-Deficient HSPC Phenotypes*
10. ESH, AML 6th International Conference 10/31/2023
    Title: *Surface Antigen Targeting in AML: CD47 and Beyond*
11. NYSCF Annual Conference, Keynote Speaker 10/24/2023
    Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
12. CSHL Meeting, Cell State Conversions 10/13/2023
    Title: *Reprogramming Cancer into Antigen Presenting Cells for Cancer Vaccination*
13. ESH, CML 25th Annual Meeting 10/6/2023
    Title: *Therapeutic Targeting of CD47 in Myeloid Malignancies*
14. Japanese Cancer Association, 82nd Annual Meeting 9/21/2023
    Title: *Pre-Leukemic Hematopoietic Stem Cells in Human AML*
15. iwAL 2023, 5th International Workshop on Acute Leukemia 8/26/2023
    Title: *Clonal Evolution in Human AML*
16. FASEB, Hematologic Malignancies 8/08/2023
    Title: *Stem Cells in Human AML*
17. GEN Webinar 6/26/2023
    Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
18. Acute Leukemias 18th Meeting 3/19/2023
    Title: *Convergent Epigenetic Evolution Drives AML Relapse*
19. Intercepting Blood Cancers, Conference 3/4/2023
    Title: *Pre-Clinical Studies Targeting Clonal Hematopoiesis HSPCs*
20. 4th Scientific Workshop: ESH: Hematologic Tumor Microenvironment 2/7//2023
    Title: *Targeting of the Macrophage Immune Checkpoint CD47 in AML*
21. AACR Special Conference, AML and MDS 1/24/2023
    Title: *Stem Cells in Human AML*
22. Nature Conference, RNA at the Bench and Bedside III 11/10/2022
    Title: *Circular RNA Uptake Programs Systemic Immunity*
23. 3rd Functional Precision Medicine in Blood Cancers 9/6/2022
    Title: *Precision Medicine in AML*
24. 1st International Workshop on MDS, 2022 6/26/2022
    Title: *ASXL1 Role in Pathogenesis of MDS*
25. New Directions in Leukaemia Research, 2022 Conference 5/31/2022
    Title: *Stem Cells and Reprogramming in Acute Leukemia*
26. Acute Leukemia Forum, 26th Annual: Ernest Beutler Memorial Lecture 5/06/2022
    Title: *The Development of CD47 Antibodies in Myeloid Malignancies*
27. Stanford Center for Definitive and Curative Medicine,6th Annual Symposium 3/24/2022
    Title: *Reprogramming B-ALL into APCs for Cancer Vaccination*
28. American Society for Hematology, ASH-EHA Session, Annual Meeting 2021 12/12/2021
    Title: The *CD47-SIRPalpha Signaling Pathway in Cancer Therapy*
29. EvansMDS Workshop on Myelodysplastic Syndromes 11/05/2021
    Title: *ASXL1 Mutations in Clonal Hematopoiesis*
30. International Clinical Cytometry Society, 2021 Conference 10/11/2021
    Title: *Role of Single Cell Technologies in AML MRD Detection*
31. American Association for Cancer Research, Clonal Hematopoiesis Meeting 8/19/2021
    Title: *ASXL1 Mutations in Clonal Hematopoiesis*

32. European Hematology Association, Annual Meeting 2021 6/17/2021
    Title: *Targeting of the Macrophage Immune Checkpoint CD47 in AML*
33. 3rd International Workshop on Acute Leukemias 4/29/2021
    Title: *Modeling Human Pre-Leukemic HSCs Using CRISPR*
34. Keystone Meeting, Hematopoiesis 4/24/2021
    Title: *Reprogramming B-ALL into APCs for Cancer Vaccination*
35. Frontiers in Blood Cancer and Development, International Symposium 3/1/2021
    Title: *Modeling Human Pre-Leukemic HSCs Using CRISPR*
36. Runx1 Research Program, 4th Annual Scientific Conference 11/9/2020
    Title: *Runx1-Deficiency Human CD34+ HSPCs*
37. ASBMR 2020 Annual Meeting 9/15/2020
    Title: *Modeling Human Hematologic Malignancies in the Bone Marrow Microenvironment*
38. ISSCR 2020, Annual Meeting 6/26/2020
    Title: *Modeling Human Pre-Leukemic Hematopoietic Stem Cells Using CRISPR*
39. ASH Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies 12/06/2019
    Title: *Modeling RUNX1 FPD/AML Mutations in Primary Human HSPCs*
40. ESH 5th International Conference, Acute Myeloid Leukemia, Estoril, Portugal 10/25/2019
    Title: *Therapeutic Targeting of the Macrophage Checkpoint Inhibitor CD47 in AML*
41. ESH 5th International Conference, Acute Myeloid Leukemia, Estoril, Portugal 10/24/2019
    Title: *Stem Cells in Human AML*
42. RUNX1 Research Program, 3rd Annual Scientific Conference 10/03/2019
    Title: *Modeling FPD/AML RUNX1 Mutations in Primary Human HSPCs*
43. Forbeck Research Forum, Leukemia Stem Cells, Denver, CO 9/13/2019
    Title: *Stem Cells in Human AML*
44. FASEB, The Hematologic Malignancies Conference, Snowmass, CO 7/30/2019
    Title: *Stem Cells in Human AML*
45. Joint International Conference, Foundazione Michelangelo, Milan, Italy 7/4/2019
    Title: *Development of a Humanized Anti-CD47 Antibody*
46. JSH, 10th Annual International Meeting, Ise, Japan 5/18/2019
    Title: *Clonal Evolution of Human AML*
47. JSH, 10th Annual International Meeting, Ise, Japan 5/17/2019
    Title: *Stem Cells in Human AML*
48. iWAL 2019, 2nd International Workshop on Acute Leukemia, Barcelona 5/04/2019
    Title: *Stem Cells in Human AML*
49. iCKSH, 60th Annual Meeting, Seoul 3/24/2019
    Title: *Stem Cells in Human AML*
50. Acute Leukemias XVII, Munich 2/24/2019
    Title: *Stem Cells in Human AML*
51. RUNX1 Research Program, Annual Scientific Meeting 11/05/2018
    Title: *Characterization of Pre-Leukemia Associated with Familial RUNX1 Mutations*
52. International Society for Experimental Hematology, 47th Annual Meeting 08/26/2018
    Title: *Stem Cells in Human AML*
53. 9th JSH International Symposium 2018 in Kyoto 07/26/2018
    Title: *Epigenetic Dysregulation in Human AML Stem Cells*
54. 12th Myeloid Workshop, Cincinnati 05/10/2018
    Title: *Metabolic Differences Between IDH1 and IDH2 Mutant AML Yield Therapeutic Vulnerabilities*
55. 21st International RUNX Conference 11/13/2017
    Title: *Characterization of Pre-Leukemic HSPCs with Engineered FPD/AML RUNX1 Mutations*
56. 4th International Conference on AML, European School of Hematology 10/6/2017
    Title: *Stem Cells in Human AML*
57. 4th International Conference on AML, European School of Hematology 10/6/2017
    Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody*
58. FASEB Meeting, Hematologic Malignancies 7/25/2017
    Title: *Stem Cells in Human AML*
59. Pharmaceutical and BioScience Society, Minisymposium 6/28/2017
    Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody*

60. Acute Leukemias XVI, Munich 2/19/2017
    Title: *Epigenetics in Human AML: Leukemia-Associated Cohesin Mutations and AML-Derived iPSCs*
61. Keystone Meeting, Hematopoiesis 2/4/2017
    Title: *Stem Cells in Human AML*
62. 7th Biennial Workshop, Clinical Translation of Epigenetics in Cancer Therapy 1/15/2017
    Title: *Pluripotent Reprogramming of Human AML Resets Leukemic Behavior and Models Therapeutic Targeting of Subclones*
63. American Society of Hematology, 2016 Annual Meeting Scientific Session 12/3/2016
    Title: *Chromatin Accessibility Charts Human Hematopoiesis and AML Evolution*
64. American Society of Hematology, 2016 Annual Meeting Workshop 12/2/2016
    Title: *CD47/SIRPalpha Directed Therapy to Reverse Macrophage Inhibition*
65. New York Stem Cell Foundation, 11th Annual Meeting 10/26/2016
    Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody*
66. 91st Stem Cell Biology and Regenerative Medicine Forum, University of Tokyo 10/17/2016
    Title: *Stem Cells in Human AML*
67. Japanese Society of Hematology, 78th Annual Meeting 10/13/2016
    Title: *Pre-Leukemic Hematopoietic Stem Cells in Human AML*
68. Hematological Malignancies: From Mechanisms to Therapy, Milan, Italy 3/10/2016
    Title: *Pre-Leukemic Hematopoietic Stem Cells in Human AML*
69. 5th International Workshop on Humanized Mice, Zurich, Switzerland 1/28/2016
    Title: *A Novel Humanized Bone Marrow Niche Xenotransplantation Model Allows Superior Engraftment of Human Normal and Malignant Hematopoiesis*
70. American Society of Hematology, 2015 Annual Meeting Scientific Program 12/5/2015
    Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
71. 8th International Conference on WT1 in Human Neoplasia 11/19/2015
    Title: *Mutant WT1 is Associated with DNA Hypermethylation of PRC2 Targets in AML and Responds to EZH2 Inhibition*
72. Society of Hematologic Oncology, 2015 Annual Meeting 9/19/2015
    Houston, Texas
    Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
73. ESH International Conference on AML 9/11/2015
    Budapest, Hungary
    Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
74. ESH International Conference on AML 9/10/2015
    Budapest, Hungary
    Title: *IDH1/2 Mutations Induce BCL-2 Dependence in Acute Myeloid Leukemia*
75. Working Conference on the Classification and Nomenclature of Clonal Conditions 8/21/2015
    Vienna, Austria
    Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
76. European Hematology Association, 2015 Annual Meeting, Plenary Session 6/14/2015
    Vienna, Austria
    Title: *Tracking and Targeting Leukemia Stem Cells*
77. International Society for Experimental Hematology - Webinar 6/03/2015
    Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
78. 7th Biennial Workshop, Clinical Translation of Epigenetics in Cancer Therapy
    St. Augustine, Florida 1/17/2015
    Title: *Mutant WT1 is Associated with DNA Hypermethylation of PRC2 Targets in AML and Responds to EZH2 Inhibition*
79. 2014 World Alliance Forum in San Francisco on Stem Cell Research and Regenerative Medicine
    San Francisco, California 11/06/2014
    Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody Targeting AML Stem Cells*
80. American Association for Cancer Research, Hematologic Malignancies: Translating Discoveries to Novel Therapies
    Philadelphia, Pennsylvania 9/21/2014
    Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody Targeting AML Stem Cells*
81. International Society for Experimental Hematology, Annual Meeting

Montreal, Canada 8/23/2014
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*

82. Leukemia and Lymphoma Society, Annual Scientific Meeting
Washington D.C. 5/05/2014
Title: *A Bispecific Antibody Targeting CD47 and CD20 Selectively Binds and Eliminates Dual Antigen Expressing NHL Cells*
83. Acute Leukemia Forum 2014
San Francisco, California 4/25/2014
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
84. 8th Sino-US Symposium on Medicine in the 21st Century
Shanghai, China 11/16/2013
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Malignancies*
85. Nature Biotechnology SciCafe
San Francisco, California 11/07/2013
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
86. 2013 Annual Meeting, Japanese Society of Hematology
Sapporo, Japan 10/08/2013
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
87. 2nd International Michelangelo Conference
Milan, Italy 7/05/2013
Title: *Antibody Therapy Targeting CD47*
88. 1st Annual, Shanghai International Workshop on Stem Cells and Cancer
Shanghai, China 4/19/2013
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
89. 2013 Bone Marrow Transplant Tandem Meetings
Salt Lake City, Utah 2/14/2013
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
90. Charles Rodolphe Brupbacher Symposium
Zurich, Switzerland 1/31/2013
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
91. American Society of Hematology, Myeloid Workshop
Atlanta, Georgia 12/07/2012
Title: *Pre-Clinical Development of a Humanized Anti-CD47 Antibody for the Treatment of AML*
92. Regenerative Medicine Seminar Series, Stanford University
Stanford, California 11/29/2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
93. German Cancer Research Center (DKFZ), 2nd Symposium, Targeted Cancer Therapy
Heidelberg, Germany 11/20/2012
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*
94. German Society of Hematology and Oncology (DGHO), Annual Meeting – Plenary Session
Stuttgart, Germany 10/20/2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
95. New York Stem Cell Foundation, Annual Meeting
New York, New York 10/12/2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
96. American Society of Clinical Oncology, Annual Meeting
Chicago, Illinois 6/04/2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
97. Integrative Cancer Biology Program, NCI Steering Committee Meeting
Burlingame, California 5/08/2012
Title: *Identification of Key Drivers of Human AML Stem Cell Pathogenesis*
98. Center for Cancer Systems Biology, 2nd Annual Symposium, Stanford University
Stanford, California 5/07/2012
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*
99. American Association for Cancer Research, 103nd Annual Meeting
Chicago, Illinois 4/03/2012

Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*

100. American Society of Hematology, 53rd Annual Meeting – Plenary Session
San Diego, California 12/09/2011
Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*

101. University of Sao Paulo Conference on Stem Cells
Sao Paulo, Brazil 10/24/2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*

102. 20th Anniversary Symposium of GRAN
Tokyo, Japan 10/01/2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*

103. Stem Cell Research Symposium, Kyushu University
Fukuoka, Japan 9/29/2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Malignancies*

104. 2nd Meeting, Experimental Hematology, CEINGE
Naples, Italy 6/29/2011
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*

105. European Hematology Association, 16th Annual Meeting
London, England 6/12/2011
Title: *Monoclonal Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells*

106. Center for Cancer Systems Biology, 1st Annual Symposium, Stanford University
Stanford, California 5/03/2011
Title: *Computational and Functional Approaches to Investigation of Leukemia Stem Cells in AML*

107. American Association for Cancer Research, 102nd Annual Meeting
Washington D.C. 4/02/2011
Title: *Therapeutic Targeting of Cancer Stem Cell Survival Mechanisms*

108. American Association for Cancer Research, 102nd Annual Meeting
Washington D.C. 4/02/2011
Title: *Isolation of Normal Hematopoietic Stem Cells and Acute Myeloid Leukemia Stem Cells*

109. CIRM - India Institute for Stem Cell Biology (inSTEM) Collaborative Meeting
Bangalore, India 3/21/2011
Title: *Clinical Significance and Prospective Separation of Leukemia Stem Cells in AML*

110. City of Hope, Innovative Partnerships: Bringing Stem Cell Discoveries to the Clinic
City of Hope, California 11/18/2010
Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*

111. NHLBI, Progenitor Cell Biology Consortium Meeting
Seattle, Washington 10/21/2010
Title: *Single Cell Phospho-Flow Cytometry Reveals Human HSC Respond Directly to Numerous Cytokines*

112. Japanese Society of Hematology, 72nd Annual Meeting
Yokohama, Japan 9/24/2010
Title*: Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*

113. Intl Conference, Stem Cells: the Diverging Goals of Regenerative Medicine and Oncology
Rome, Italy 7/02/2010
Title*: Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*

114. American Association for Cancer Research, 101st Annual Meeting
Washington D.C. 4/17/2010
Title*: Targeting CD47 with Blocking Monoclonal Antibodies in Human Hematologic Malignancies*

115. 17th International Molecular Medicine Tri-Conference
San Francisco, California 2/08/2010
Title*: CD47: An Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells*

116. International Society for Stem Cell Research, 8th Annual Meeting
San Francisco, California 6/18/2010
Title*: TIM-3 Is a Novel Human Acute Myeloid Leukemia Marker that Enables the Prospective Separation of Normal and Leukemia Stem Cells*

117. IBC 20th Annual International Conference, Antibody Engineering

San Diego, California 12/08/2009
Title*: Blocking monoclonal antibodies directed against CD47 preferentially enable phagocytosis and elimination of human acute myeloid leukemia stem cells*

118. AACR-NCI-EORTC Conference, Molecular Targets and Cancer Therapeutics
Boston, Massachusetts 11/18/2009
Title: *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*

119. Keystone Meeting, Antibodies as Drugs
Whistler, British Columbia, Canada 3/29/2009
Title*: Blocking monoclonal antibodies directed against CD47 preferentially enable phagocytosis and elimination of human acute myeloid leukemia stem cells*

120. American Society of Hematology, 50th Annual Meeting
San Francisco, California 12/07/2008
Title: *CD47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*

121. Gordon Research Conference, Stem Cells and Cancer
Big Sky Resort, Montana 9/12/2007
Title: *Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood*

122. American College of Rheumatology, 64th Annual Meeting, Plenary Session 2000
Title: *An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity*

123. Keystone Meeting, Signaling 2000 1998
Title: *Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge*

Invited Seminars

1. Albert Einstein Medical College, New York 2024
Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
2. Dana-Farber Cancer Center, Boston 2024
Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
3. University of Miami, Cancer Center Lecture Series 2023
Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
4. University of Wisconsin, Cancer Biology Seminar 2023
Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
5. University of California, San Diego: Helen Ranney Lecture 2022
Title: *Stem Cells in Human Acute Leukemia*
6. University of Arizona, Cancer Biology Seminar 2022
Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
7. USC Stem Cell Institute Seminar 2022
Title: *Stem Cells and Reprogramming in Human Acute Leukemia*
8. MD Anderson Cancer Center, Experimental Therapeutics Seminar 2022
Title: *Stem Cells in Human AML*
9. Ohio State University Comprehensive Cancer Center Grand Rounds 2021
Title: *Stem Cells in Human AML*
10. Dana Farber Cancer Institute, Heme-BMT Grand Rounds 2021
Title: *Stem Cells in Human AML*
11. Erasmus Cancer Center, Netherlands 2021
Title: *Stem Cells in Human AML*
12. Indiana University, Cancer Center Seminar 2021
Title: *Stem Cells in Human AML*
13. Massachusetts General Hospital, Cancer Center Seminar 2021
Title: *Stem Cells in Human AML*
14. The Scientist Webinar 2020
Title: *Multiomic Single Cell Analysis Identifies a Unique Stem and Progenitor*

15. Stanford Hematology, Annual ASH Review 2020
    Title: *Stem Cells in Human AML*
16. Stanford University, Department of Medicine Grand Rounds 2019
    Title: *Development of a Humanized Anti-CD47 Antibody*
17. Dana Farber Cancer Institute, Hematologic Malignancies Grand Rounds 2019
    Title: *Stem Cells in Human AML*
18. Boston Children's Hospital, Pediatric Oncology Seminar 2019
    Title: *Stem Cells in Human AML*
19. Pharmacyclics 2018
    Title: *Stem Cells in Human AML*
20. University of Colorado 2018
    Title: *Stem Cells in Human AML*
21. University of Kyoto 2018
    Title: *Stem Cells in Human AML*
22. Genentech Safety Science Retreat 2018
    Title: *AML and Development of a Humanized Anti-CD47 Antibody*
23. Sanford Burnam Institute, San Diego 2018
    Title: *Stem Cells in Human AML*
24. University of Toronto 2017
    Title: *Stem Cells in Human AML*
25. Fox Chase Cancer Center, Philadelphia 2017
    Title: *Stem Cells in Human AML*
26. University of California, Irvine – MSTP Retreat 2017
    Title: *Stem Cells in Human AML*
27. San Raffaele Scientific Institute, Milan 2017
    Title: *Stem Cells in Human AML*
28. British Columbia Cancer Research GrasPods Keynote Address 2017
    Title: *Stem Cells in Human AML*
29. Northwestern Medical School, Department of Biochemistry and Molecular Genetics Seminar 2017
    Title: *Stem Cells in Human AML*
30. Fudan Medical School, Shanghai, China 2016
    Title: *Stem Cells in Human AML*
31. UCSD, Genomics, Bioinformatics, and Systems Biology Colloquium 2016
    Title: *Stem Cells in Human AML*
32. City of Hope, Leukemia Seminar Series 2016
    Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
33. Memorial Sloan Kettering Cancer Center, Medicine Grand Rounds 2016
    Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
34. University of Chicago, Cancer Center Seminar Series 2016
    Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
35. Agios Pharmaceuticals, Cambridge, MA 2015
    Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
36. Dana Farber Cancer Institute, BMT Grand Rounds 2015
    Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
37. Cleveland Clinic, Stem Cell Institute 2015
    Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
38. MD Anderson Cancer Center, Leukemia Grand Rounds 2014
    Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
39. Albert Einstein School of Medicine – Stem Cell Institute 2013
    Title: *AML Stem Cells: Isolation, Clinical Significance, and Therapeutic Targeting*
40. University of California, San Francisco – Cancer Center 2013
    Title: *AML Stem Cells: Isolation, Clinical Significance, and Therapeutic Targeting*
41. University of Texas, Southwestern – Children's Research Institute 2012
    Title: *AML Stem Cells: Isolation, Clinical Significance, and Therapeutic Targeting*
42. PACTTE/NHLBI – Webinar 2012
    Title: *Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells Precedes Human AML*

43. Agilent Technologies, Santa Clara, California 2012
    Title: *Characterization of Normal HSC and AML Stem Cells*
44. Epply Institute, University of Nebraska – Omaha, Cancer Short Course 2012
    Title: *AML Stem Cells: Biology, Clinical Significance, and Therapeutic Targeting*
45. American Association of Clinical Chemistry, Southern California Section 2012
    Title: *Clinical Significance, Isolation, and Targeting of Leukemia Stem Cells in AML*
46. Chinese American Biopharmaceutical Society, Foster City, California 2011
    Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
47. Memorial Sloan Kettering Cancer Center, New York, New York 2011
    Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
48. Pfizer (Rinat), South San Francisco, California 2011
    Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
49. LSU Cancer Center, New Orleans, Louisiana 2010
    Title: *Targeting CD47 with Blocking Monoclonal Antibodies in Hematologic Malignancies*
50. MD Anderson Cancer Center, Houston, Texas 2010
    Title: *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
51. Weatherall Institute of Molecular Medicine, University of Oxford, United Kingdom 2009
    Title: *CD47 is an independent prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*
52. Genentech, Inc., South San Francisco, California 2009
    Title: *CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells*

Intellectual Property / Patents

Awarded Patents

U.S. Patent No. 8,361,736 2013
Ex Vivo Methods for Targeting or Depleting Acute Myeloid Leukemia Cancer Stem Cells

U.S. Patent No. 8,562,997 2013
Methods of Treating Acute Myeloid Leukemia by Blocking CD47

U.S. Patent No. 8,709,7429; 9,193,955; 9,796,781; 10,662,242 2014-2020
Markers of Acute Myeloid Leukemia Stem Cells

U.S. Patent No. 8,758,750 2014
Synergistic Anti-CD47 Therapy for Hematologic Cancers

U.S. Patent No. 9,017,675; 9,382,320 2015
Humanized and Chimeric Monoclonal Antibodies to CD47

U.S. Patent No. 9,399,682; 9,493,575; 9,605,076
9,611,329; 9,624,305; 9,765,143; 10,640,561 2015-2020
Methods of Manipulating Phagocytosis Mediated by CD47

U.S. Patent No. 9,623,079 2015
Methods for Achieving Therapeutically Effective Doses of Anti-CD47 Agents for Treating Cancer

U.S. Patent No. 10,040,862 2018
Humanized and Chimeric Monoclonal Antibodies to CD99

U.S. Patent No. 10,087,257; 10,487,150 2018-2019
SIRP Alpha-Antibody Fusion Proteins

U.S. Patent No. 10,301,387 2019
Methods for Achieving Therapeutically Effective Doses of Anti-CD47 Agents

Investigational New Drug (IND) Applications

IND117687 2014
Hu5F9-G4 (Humanized Monoclonal Antibody Targeting CD47 for the Treatment of Solid Tumors)

IMPD (UK) 2015
Hu5F9-G4 (Humanized Monoclonal Antibody Targeting CD47 for the Treatment of AML)

Patent Applications

US-2009191164 2009
Human Hematopoietic Multipotent Progenitor Cells

US-2014148351 2011
Prediction of Clinical Outcome in Hematological Malignancies Using a Self Renewal Expression Signature

US-2016289326 2016
Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low

Density Lipoprotein-Related Receptor

WO-2017083716 2016
Determination of Synthetic Lethal Partners of Cancer-Specific Alterations and Methods of Use Thereof

US-2017210803 2017
Treatment of Cancer with Combinations of Immunoregulatory Agents

US-2020048369 2017
Modified Immunoglobulin Hinge Regions to Reduce Hemagglutination

US-2020147212 2018
Dosing Parameters for CD47 Targeted Therapies in Hematologic Malignancies

WO-2020180706 2020
Therapeutic Antigen Binding Proteins Specific for CD93 and Methods of Use Thereof

WO-2020210225 2020
Barcoded Clonal Tracking of Gene Targeting in Cells

PCT/US2020/058170 2020
Lineage Reprogramming as a Cancer Immunotherapy

PCT/US2021/024937 2021
Pharmaceutical Formulation of Hu5F9-G4 for Human Therapeutic Use

US 63/244,636 2021
Compositions of Chimeric Antigen Receptor (CAR) Signaling Molecules and Uses Thereof